PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12909330-7 2003 The thrombin-induced rise in MLC phosphorylation was sensitive to reduction of [Ca(2+)](i) It was accompanied by an increase in Rho activation, and was inhibited by Y-27632 (10 microM), a Rho-kinase blocker. Y 27632 165-172 coagulation factor II, thrombin Homo sapiens 4-12 12770938-8 2003 5 When EC were preincubated with the specific Rho kinase (ROCK) inhibitor Y-27632, we observed a reduction in PMN adherence in response to thrombin, as well as a decrease in thrombin-stimulated IL-8 production. Y 27632 74-81 coagulation factor II, thrombin Homo sapiens 139-147 12770938-8 2003 5 When EC were preincubated with the specific Rho kinase (ROCK) inhibitor Y-27632, we observed a reduction in PMN adherence in response to thrombin, as well as a decrease in thrombin-stimulated IL-8 production. Y 27632 74-81 coagulation factor II, thrombin Homo sapiens 174-182 11577023-9 2001 Inhibition of Rho A by C3 exoenzyme (20 microgram/mL) and ROCK by Y-27632 (10 micromol/L) prevented the downregulation of eNOS expression by thrombin. Y 27632 66-73 coagulation factor II, thrombin Homo sapiens 141-149 11956113-13 2002 Akt dephosphorylation by thrombin was blocked by both simvastatin and Y-27632. Y 27632 70-77 coagulation factor II, thrombin Homo sapiens 25-33 11577023-10 2001 Y-27632 also prevented the reduction in NOS activity induced by prolonged incubation with thrombin. Y 27632 0-7 coagulation factor II, thrombin Homo sapiens 90-98 11257000-5 2001 Dominant-negative RhoA and a Rho kinase inhibitor, Y-27632, not only inhibit stress fibre assembly and contractility but also prevent thrombin- and histamine-induced disassembly of adherens and tight junctions in endothelial cells, providing an explanation for their effects on permeability. Y 27632 51-58 coagulation factor II, thrombin Homo sapiens 134-142 11549255-4 2001 The thrombin- and GTPgammaS-induced MLC-P in constant [Ca(2+)](i) was inhibited by the addition of Y27632, a Rho-kinase inhibitor. Y 27632 99-105 coagulation factor II, thrombin Homo sapiens 4-12 10497186-7 1999 ADP, thrombin, or U46619-induced Ca(2+)-independent platelet shape change was significantly reduced by staurosporine, a nonselective kinase inhibitor, by the selective p160 Rho-associated coiled-coil-containing protein kinase inhibitor Y-27632, or by HA 1077. Y 27632 236-243 coagulation factor II, thrombin Homo sapiens 5-13 10948069-9 2000 In the presence of Y-27632, the thrombin-enhanced permeability was additionally reduced by chelation of [Ca(2+)](i) by BAPTA. Y 27632 19-26 coagulation factor II, thrombin Homo sapiens 32-40 10233893-7 1999 In addition, HA1077 and Y-27632 inhibited 20-kD MLC phosphorylation at Ser19 and ATP secretion of platelets stimulated with STA2, thrombin (0.05 U/mL), and simultaneous addition of serotonin and epinephrine, whereas these compounds did not affect MLC phosphorylation or ATP secretion when platelets were stimulated with more than 0.1 U/mL thrombin. Y 27632 24-31 coagulation factor II, thrombin Homo sapiens 130-138 10233893-7 1999 In addition, HA1077 and Y-27632 inhibited 20-kD MLC phosphorylation at Ser19 and ATP secretion of platelets stimulated with STA2, thrombin (0.05 U/mL), and simultaneous addition of serotonin and epinephrine, whereas these compounds did not affect MLC phosphorylation or ATP secretion when platelets were stimulated with more than 0.1 U/mL thrombin. Y 27632 24-31 coagulation factor II, thrombin Homo sapiens 339-347 28464379-6 2017 Neutralizing antibodies to integrin alphav, beta1, alphavbeta3, alphavbeta5, and Rho-associated coiled-coil forming protein kinase (ROCK) inhibitor Y27632 completely blocked thrombin-induced TGF-beta1 activation, Smad3 phosphorylation, and CCN2 synthesis. Y 27632 148-154 coagulation factor II, thrombin Homo sapiens 174-182 26391563-8 2015 In contrast, inhibition of the Rho kinase pathway using the specific inhibitor, Y27632, suppressed both the decrease in the expression of GLAST and the decrease in glutamate uptake induced by thrombin. Y 27632 80-86 coagulation factor II, thrombin Homo sapiens 192-200 30234377-6 2019 In human pulmonary microvascular endothelial cells (PMVECs), thrombin-induced loss of transendothelial electrical resistance was attenuated by a Cx40-inhibiting mimetic peptide (40GAP27), Cx40-specific shRNA, or ROCK inhibitor Y27632. Y 27632 227-233 coagulation factor II, thrombin Homo sapiens 61-69 23638866-5 2013 In the presence of agonists including thrombin, histamine, and H2O2, force correlation length increases, whereas in the presence of antagonists including sphingosine-1-phosphate, hepatocyte growth factor, and the rho kinase inhibitor, Y27632, force correlation length decreases. Y 27632 235-241 coagulation factor II, thrombin Homo sapiens 38-46 27681226-6 2016 Addition of Y27632, a RhoA inhibitor, NSC23766 or Phox-I, an inhibitor of Rac1-p67phox interaction, to human platelets blocked thrombin induced ROS generation. Y 27632 12-18 coagulation factor II, thrombin Homo sapiens 127-135 22171066-6 2012 Lysophosphatidic acid, sphingosine-1-phosphate (S1P) and thrombin caused an increase in cell stiffness by up to 200 per cent, whereas in most cell strains, exposure to latrunculin A, isoproterenol, dibutryl cyclic-AMP or Y-27632 caused a decrease in cell stiffness by up to 80 per cent, highlighting that SC cells possess a remarkably wide contractile scope. Y 27632 221-228 coagulation factor II, thrombin Homo sapiens 57-65 24021807-4 2013 Pretreatment of thrombin-induced microglia with argatroban or Y-27632 significantly decreased phagocytotic capacity and reduced ROCK, NO and TNF-alpha expression. Y 27632 62-69 coagulation factor II, thrombin Homo sapiens 16-24 23951242-10 2013 In endothelial cells, LIMK-mediated cofilin phosphorylation after thrombin-stimulation of EGFP- or DsRed2-tagged cofilin transfected cells reduced cofilin aggregate formation, whereas inhibition of cofilin phosphorylation after Rho-kinase inhibitor (Y27632) treatment of endothelial cells promoted formation of cofilin aggregates. Y 27632 250-256 coagulation factor II, thrombin Homo sapiens 66-74 20639439-10 2010 A Rho-kinase inhibitor, Y27632, inhibited not only the thrombin-induced Ca2(+)- and MLC20 phosphorylation-dependent contraction, but also the Ca2(+)- and MLC20 phosphorylation-independent contraction and the ROS production. Y 27632 24-30 coagulation factor II, thrombin Homo sapiens 55-63 15284075-5 2004 Reductions in MLC phosphorylation induced by cell pretreatment with pharmacological inhibitors of MLC kinase (ML-7) and Rho kinase (Y-27632) significantly attenuated thrombin-mediated TER changes and MLC phosphorylation in both lung cell types. Y 27632 132-139 coagulation factor II, thrombin Homo sapiens 166-174 19064940-9 2009 We further demonstrated that inhibition of Rho with C3 exoenzyme or dominant negative (dn) RhoA, and inhibition of Rho-Kinase (ROCK) with Y-27632 caused a significant decrease in thrombin and TFLLR-induced Thr495 phosphorylation. Y 27632 138-145 coagulation factor II, thrombin Homo sapiens 179-187 19133144-11 2009 Y-27632 decreased both basal and thrombin-induced collagen contractility in the hTERT-HM embedded gels. Y 27632 0-7 coagulation factor II, thrombin Homo sapiens 33-41 19574550-4 2009 Thrombin-stimulated upregulation of the transcription factor myocardin and smooth muscle myosin heavy chain, and both were inhibited by hirudin or the RhoA inhibitor Y27632. Y 27632 166-172 coagulation factor II, thrombin Homo sapiens 0-8 19574550-7 2009 Thrombin-induced enhancement of smooth muscle outgrowth colony formation was inhibited by hirudin, Y27632, and an antibody against protease-activated receptor-1. Y 27632 99-105 coagulation factor II, thrombin Homo sapiens 0-8 17651694-8 2007 Treatment with Y27632, a Rho-kinase inhibitor, suppressed thrombin-induced phosphorylation at Thr495. Y 27632 15-21 coagulation factor II, thrombin Homo sapiens 58-66 16675616-8 2006 Disruption of actin cytoskeleton with cytochalasin D (5 microM, 30 min) and inhibition of myosin light chain kinase with ML-7 (10 microM, 30 min) and Rho kinase with Y-27632 (10 microM, 30 min) markedly depressed basal contractile tone and abolished thrombin-induced cell contraction. Y 27632 166-173 coagulation factor II, thrombin Homo sapiens 250-258 15569838-4 2004 The effect of thrombin was prevented by C3 exoenzyme or the HMG-CoA reductase inhibitor fluvastatin, which inhibit RhoA, or by the ROCK inhibitors Y-27632 and HA-1077. Y 27632 147-154 coagulation factor II, thrombin Homo sapiens 14-22 14709404-7 2004 The specific Rho-kinase inhibitor, Y27632, abolished MYPT1 phosphorylation, MLC phosphorylation, significantly attenuated stress fiber formation and thrombin-induced TER decrease. Y 27632 35-41 coagulation factor II, thrombin Homo sapiens 149-157